In a typical foundry, raw materials like steel and copper are melted down and poured into molds to assume new shapes and functions. The U.S. National Science Foundation Artificial Intelligence-driven RNA Foundry (NSF AIRFoundry), led by the University of Pennsylvania and the University of Puerto Rico and supported by an $18-million, six-year grant, will serve much the same purpose, only instead of smithing metal, the "BioFoundry" will create molecules and nanoparticles.
NSF AIRFoundry is one of five newly created BioFoundries, each of which will have a different focus. Bringing together researchers from Penn Engineering, Penn Medicine's Institute for RNA Innovation, the University of Puerto Rico–Mayagüez (UPR-M), Drexel University, the Children's Hospital of Philadelphia (CHOP) and InfiniFluidics, the facility, which will be physically located in West Philadelphia and at UPR-M, will focus on ribonucleic acid (RNA), the tiny molecule essential to genetic expression and protein synthesis that played a key role in the COVID-19 vaccines and saved tens of millions of lives.
The facility will use AI to design, optimize and synthesize RNA and delivery vehicles by augmenting human expertise, enabling rapid iterative experimentation, and providing predictive models and automated workflows to accelerate discovery and innovation.
With NSF AIRFoundry, we are creating a hub for innovation in RNA technology that will empower scientists to tackle some of the world's biggest challenges, from health care to environmental sustainability."
Daeyeon Lee, PhD, the Russell Pearce and Elizabeth Crimian Heuer Professor in Chemical and Biomolecular Engineering in Penn Engineering and NSF AIRFoundry's director
"Our goal is to make cutting-edge RNA research accessible to a broad scientific community beyond the health care sector, accelerating basic research and discoveries that can lead to new treatments, improved crops and more resilient ecosystems," added Nobel laureate Drew Weissman, MD, PhD, the Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania, Penn Medicine, the director of the Penn Institute for RNA Innovation, and the NSF AIRFoundry's senior associate director.
The facility will catalyze new innovations in the field by leveraging artificial intelligence (AI). AI has already shown great promise in drug discovery, poring over vast amounts of data to find hidden patterns. "By integrating artificial intelligence and advanced manufacturing techniques, the NSFAIRFoundry will revolutionize how we design and produce RNA-based solutions," said David Issadore, PhD, a professor in Bioengineering and in Electrical and Systems Engineering at Penn Engineering and the facility's associate director of research coordination.
InfiniFluidics, a Philadelphia-based startup co-founded by Lee and Issadore, along with collaborators from UPR-M, Drexel and CHOP will work closely to improve the design and manufacture of lipid nanoparticles (LNPs), the tiny, fatty vessels that can deliver RNA inside cells. Just as foundries provide other manufacturers with metal, NSF AIRFoundry will supply any lab, biotechnology company or pharmaceutical firm with high-quality, customizable ingredients for RNA and LNP experiments.
In addition, the facility will foster collaboration among RNA scientists with an AI-powered platform. "The knowledge-sharing platform we are developing will allow researchers to collaborate and share insights in ways that were never before possible," said Zachary Ives, PhD, Adani President's Distinguished Professor in Computer and Information Science at Penn Engineering and NSF AIRFoundry's associate director of knowledge sharing.
The facility will also democratize research and train the next generation of RNA scientists by offering educational programs, workshops and research opportunities. "We are not only advancing scientific knowledge but also broadening participation, ensuring that students and scientists from all backgrounds have the opportunity to contribute to and benefit from this emerging field," said Claribel Acevedo-Vélez, PhD, an associate professor in Chemical Engineering at UPR-M and associate director of education and diversity at NSF AIRFoundry.
Ultimately, said Lee, "NSF AIRFoundry will bring about the RNA revolution by leveraging the power of the molecules that saved millions of lives and the AI that is changing the world."
Patient-derived organoids: Transforming cancer research and personalized medicine